Voorbeelden van het gebruik van Other statins in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
At 60% the bioavailability of cerivastatin is greater than that of any of the other statins.
the incidence of confirmed, but not unconfirmed rhabdomyolysis is higher with cerivastatin than with the other statins.
which on the whole is comparable with the other statins.
However, there is no reason to believe that the beneficial effect observed following treatment with other statins would not also apply to cerivastatin.
Two further studies compared Cholib with other statins(atorvastatin and pravastatin)
No cases of confirmed rhabdomyolysis with clopidogrel co-administration were reported with the other statins, except for 3 cases with simvastatin, but no fatalities.
suspected cases of rhabdomyolysis in association with cerivastatin monotherapy is greater than that seen with any of the other statins.
equipotent doses of the other statins is provided in Table 5 and 6.
In addition, concomitant use of pazopanib and other statins should be undertaken with caution as there are insufficient data available to assess their impact on ALT levels.
equipotent dose of the other statins.
10xULN for cerivastatin 0.1mg to 0.3mg are similar to that seen with other statins.
that the hospitalisation rate for myopathy associated with the use of cerivastatin monotherapy was not increased relative to the other statins.
The updated data from the FDA database suggests that the reporting rates of confirmed cases of rhabdomyolysis in association with 0.2mg to 0.8mg cerivastatin monotherapy are greater than those with any of the other statins.
10 to 50 times higher than the rates associated with the other statins.
the incidence of these events with 0.8mg cerivastatin is higher than that for lower dosages of cerivastatin and other statins.
The data for use of gemfibrozil with the other statins also suggest an increased risk however the disproportion between the reporting rate on combination treatment
therefore the higher incidence seen with cerivastatin compared with the other statins should be interpreted with caution, is accepted.
Unlike some of the other statins, there are no data to demonstrate the efficacy of cerivastatin in either primary or secondary prevention of coronary heart disease
plasma levels of pravastatin, as have been seen with other statins.